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Tumours ferment glucose to lactate even in the presence of oxygen (aerobic glycolysis; Warburg effect). The pentose phosphate
pathway (PPP) allows glucose conversion to ribose for nucleic acid synthesis and glucose degradation to lactate. The nonoxidative
part of the PPP is controlled by transketolase enzyme reactions. We have detected upregulation of a mutated transketolase transcript
(TKTL1) in human malignancies, whereas transketolase (TKT) and transketolase-like-2 (TKTL2) transcripts were not upregulated.
Strong TKTL1 protein expression was correlated to invasive colon and urothelial tumours and to poor patients outcome. TKTL1
encodes a transketolase with unusual enzymatic properties, which are likely to be caused by the internal deletion of conserved
residues. We propose that TKTL1 upregulation in tumours leads to enhanced, oxygen-independent glucose usage and a lactate-
based matrix degradation. As inhibition of transketolase enzyme reactions suppresses tumour growth and metastasis, TKTL1 could be
the relevant target for novel anti-transketolase cancer therapies. We suggest an individualised cancer therapy based on the
determination of metabolic changes in tumours that might enable the targeted inhibition of invasion and metastasis.
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Cancer is now viewed as a disease resulting from cancer-causing
genes that deregulate cellular proliferation, differentiation,
and death. Genetic alterations acquired by tumours also modify
their biochemical pathways, resulting in abnormal metabolism.
Warburg proposed a model of tumorigenesis involving altered
energy production in tumours. He identified a particular metabolic
pathway in carcinomas characterised by the anaerobic degradation
of glucose even in the presence of oxygen (aerobic glycolysis) that
leads to the production of large amounts of lactate (known as the
Warburg effect; Warburg et al, 1924). The relevance of aerobic
glycolysis to cancer cell biology remains controversial (Garber,
2004; Gatenby and Gillies, 2004). However, the widespread clinical
use of positron-emission tomography (PET) for the detection of
aerobic glycolysis in tumours and recent findings have rekindled
interest in Warburg’s theory. Studies on the physiological changes
in malignant conversion provided a metabolic signature for the
different stages of tumorigenesis (Ramanathan et al, 2005); during
tumorigenesis, an increase in glucose uptake and lactate production
have been detected. The fully transformed state is most dependent
on aerobic glycolysis and least dependent on the mitochondrial
machinery for ATP synthesis (Ramanathan et al,2 0 0 5 ) .
Other important links between cancer-causing genes and
glucose metabolism have been already identified. Activation of
the oncogenic kinase Akt has been shown to stimulate glucose
uptake and metabolism in cancer cells and renders these cells
susceptible to death in response to glucose withdrawal (Elstrom
et al, 2004). Such tumour cells have been shown to be dependent
on glucose because the ability to induce fatty acid oxidation in
response to glucose deprivation is impaired by activated Akt
(Buzzai et al, 2005). In addition, AMP-activated protein kinase
(AMPK) has been identified as a link between glucose metabolism
and the cell cycle, thereby implicating p53 as an essential
component of metabolic cell-cycle control (Jones et al, 2005).
These findings suggest that tumorigenesis requires derangements
in known cancer-causing genes and altered energy production.
Despite this appreciation, the reason enhanced anaerobic
glucose degradation occurs in tumours remains elusive. If
carcinogenesis occurs by somatic evolution, then common
components of the cancer phenotype result from active selection,
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sand must, therefore, confer a significant growth advantage
(Gatenby and Gillies, 2004). A prerequisite for the understanding
of the altered glucose metabolism in tumours and its predicted
selective growth advantage is the detailed analysis of glucose
degrading pathways.
Two main pathways of glucose degradation have been identified.
The observation in the 1930s that muscle extracts can catalyse the
glycolysis of glucose to lactate led to the identification of the
Embden-Meyerhof pathway. In this pathway, fructose-1,6-diphos-
phate is cleaved leading to pyruvate, which is reduced to lactate in
the absence of oxygen. In addition to this pathway, glucose is also
degraded by the pentose phosphate pathway (PPP).
The nonoxidative part of the PPP is controlled by thiamine-
(vitamin B1) dependent transketolase enzyme reactions. Transke-
tolase enzyme reactions of the nonoxidative part of the PPP enable
oxygen-independent glucose degradation, and play a crucial role in
nucleic acid ribose synthesis utilising glucose carbons in tumour
cells. More than 85% of ribose recovered from nucleic acids of
certain tumour cells is generated directly or indirectly from
the nonoxidative pathway of the PPP (Boros et al, 1997). The
importance of transketolases for tumour cell metabolism is
underlined by the fact that the application of specific transketolase
inhibitors to tumours induces a dramatic reduction in tumour cell
proliferation (Rais et al, 1999). In addition, the activation of
transketolases by application of thiamine stimulates tumour
growth (Comin-Anduix et al, 2001). Furthermore, several natural
products have been reported to inhibit transketolase enzyme
activity in vitro, and also to inhibit cell proliferation or suppress
tumour growth in mouse models or cancer patients as a result of
reduction of transketolase activity (Hidvegi et al, 1999; Boros et al,
2001a,b; Comin-Anduix et al, 2002; Jakab et al, 2003).
To establish a transketolase-inhibitory anticancer therapy, a
high throughput screening of library compounds using recombi-
nant human transketolase (TKT) has been performed. This
approach resulted in the identification of two novel small-molecule
inhibitors, which inhibit human TKT and suppress proliferation of
cancer cell lines (Du et al, 2004).
So far, three human transketolase genes have been recognised,
and the relative contributions of TKT, transketolase-like-1
(TKTL1), and transketolase-like-2 (TKTL2) to tumour-specific
transketolase metabolism have not been investigated. Here, we
provide evidence that TKTL1 mRNA and protein are specifically
overexpressed in tumours, whereas TKT and TKTL2 expression
are not upregulated. We demonstrate that TKTL1 protein is
expressed in invasive tumours and predicts poor patient survival
in colon and urothelial cancer. Our findings strongly indicate that
overexpression of TKTL1 is responsible for the observed tumour-
specific effects of transketolase enzyme reactions, and represents
the basis for the observed inhibition of proliferation of cancer cells
by anti-transketolase approaches.
MATERIALS AND METHODS
Real-time PCR and Western blot
Real-time PCR-based transcript quantification and Western blot
analysis have been described previously (Coy et al, 2005).
Subjects
In this study, 55 men and 15 women (median age of 60715 years)
with colon adenocarcinoma were included. All patients underwent
colectomy, and 30% of colon adenocarcinomas were diagnosed
as noninvasive (pTis), whereas 70% of colon adenocarcinomas
were invasive at the time of diagnosis. Eleven tumours were
classified as pT1, eight as pT2, 14 as pT3, and 16 as pT4, according
to the UICC classification.
A total of 64 patients (median age 67.5 years) with urothelial
carcinoma were enrolled in this study. Of these, 59 patients
underwent treatment for urothelial carcinoma in which: 21 under-
went transurethral resection for superficial bladder cancer; 22
underwent radical cystectomy; 16 underwent surgery for upper
urinary tract carcinomas; and five underwent surgery for benign
reasons. At the time of surgery, 14 % (8 out of 59) of the patients had
lymph node metastases. Overall, 28 tumours were classified as
nonmuscle-invasive (pTa, pT1 and carcinoma in situ)a n d3 1w e r e
classified as muscle-invasive (XpT2). Overall, 42% of the tumours
showed no or only weak staining (staining score 0 or 1), 10% showed
some staining (score 2), and 48% showed strong staining (score 3).
Patient samples
Surgical resection specimens were obtained from the Department
of Surgery, University Hospital Mannheim, Faculty of Clinical
Medicine of Ruprecht-Karls-University Heidelberg, Germany
(approval by the local Ethics Committee), and the University of
Palermo, Department of Surgical and Oncological Science, Surgery
Pathophysiology Section. None of the patients received neoadju-
vant radiotherapy or chemotherapy. From each patient, cancerous
and normal tissue was available. For RNA extraction, the speci-
mens taken during the operation were immediately snap-frozen in
liquid nitrogen and subsequently stored at  801C until use. For
immunohistochemistry (IHC), the specimens were fixed in 3.4%
buffered formalin for 24h and embedded in paraffin. Histological
diagnosis was performed by three independent, experienced
pathologists (A.z.H.; R.G.; G.S.).
Immunohistochemical staining
Three to 5mm thick paraffin sections were analysed by IHC.
Dewaxed sections were heated for antigen unmasking in 10mM
sodium citrate (pH 6.0) in a microwave oven for 1min at 450W
followed by 5min at 100W. After rinsing in dH2O, inhibition of
endogenous peroxidase was performed with a 5min incubation
with 3% H2O2. Endogenous avidin-biotin was blocked by the use of
a commercial biotin blocking system (DAKO) for 10min. After two
washes in Tris/saline buffer (TBS), slides were incubated with 1%
goat serum for 30min to block unspecific staining. Sections were
subsequently exposed to mouse anti-TKTL1 (clone JFC12T10;
mouse IgG2b) antibody (15mgml
 1) or anti-Ser473 phospho-Akt
(587F11; mouse IgG2b; Cell Signaling Technology) overnight at
41C. The monoclonal anti-TKTL1 antibody JFC12T10 has been
described previously (Coy et al, 2005). Slides were washed in TBS
and incubated with biotinylated anti-mouse immunoglobulins
for 30min at room temperature and treated with strepta-
vidin-peroxidase (DAKO). Staining was revealed using 3-amino-
9-ethylcarbazole (AEC) substrate and counter-stained with
haematoxylin (Figure 2M–T and Figure 3).
Alternatively, primary antibodies were visualised with avidin-
biotinylated horseradish peroxidase complex (ABC) and diamino-
benzidine tetrahydrochloride (DAB) (Elite kit; Vector Laboratories),
and counter-stained with Mayer’s haematoxylin (Figure 2A–L).
For scoring of TKTL1 expression, a scale from 0 to 3 was defined
as: score 0 indicates 0–20%, score 1 indicates 21–50%, score 2
indicates 51–80%, and score 3 indicates 480% of the tumour cells
were stained for TKTL1.
RESULTS
TKTL1, but not TKT or TKTL2, mRNA is overexpressed
in carcinomas
Identification of genes selectively expressed or overexpressed in
tumours is a crucial prerequisite for molecular diagnosis and
treatment of cancer by addressing molecular targets. To identify
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ssuch targets, we used the real-time PCR technique. When
comparing the transcript levels from five colon cancer tissues to
nontumour samples from the same patients, we initially detected a
35-fold overexpression of TKTL1 in one colon carcinoma sample.
As TKTL1 is one of three highly similar transketolases encoded by
three separate genes (TKT, TKTL1, TKTL2; Coy et al, 1996, 2005),
we designed primers to specifically discriminate expression of the
three transketolase genes in human carcinomas.
Using these primers, a 79-fold overexpression of the TKTL1
gene was identified in one colon carcinoma tissue, whereas none
of the tested colon carcinomas showed an overexpression of the
TKT transcript. In contrast, the TKTL2 transcript was down-
regulated more than 10-fold in three out of five colon carcinomas
(Table 1). To test whether overexpression of the TKTL1 transcript
occurs in other tumour types, cDNA from five gastric and five lung
adenocarcinomas and their corresponding normal tissues were
analysed using the real-time PCR technique. Two of five gastric
carcinomas and two of five lung adenocarcinomas had greater than
10-fold overexpression of TKTL1 (Figure 1A), whereas TKT
expression was unchanged in all tested carcinoma tissues (not
shown). Similar to its downregulation in colon carcinomas, TKTL2
expression was downregulated more than 10-fold in two of five
lung adenocarcinomas.
In the colon carcinomas depicted in Table 1, the total amount of
transketolase transcripts in four of five carcinoma tissues (Table 1;
T2–T5) was lower than that in normal tissue, even in the colon
carcinoma tissue with an overexpression of TKTL1 (Table 1; T5).
Overexpression of TKT was not detected in any of the 54
carcinoma tissue samples tested. The only transketolase gene
overexpressed in carcinoma tissue was the TKTL1 gene.
TKTL1 protein is overexpressed in human carcinomas
In order to determine TKTL1 protein expression levels in human
carcinomas, we performed IHC on 1030 human carcinomas
derived from 16 different epithelial tumour entities using a
monoclonal antibody (JFC12T10) that specifically detects TKTL1
(Coy et al, 2005). A gastric carcinoma specimen that we found to
have 1000-fold overexpression of TKTL1 mRNA when compared
to the corresponding normal tissue showed a strong overexpres-
sion of the TKTL1 protein on Western blot level (Figure 1B) as
well as a strong TKTL1 immunoreactivity on paraffin sections
(Figure 2C–G). Mainly cytoplasmic expression was detected.
TKTL1 expression was restricted to tumour cells, and the
surrounding stromal tissue showed no staining. In the correspond-
ing normal tissue, no staining was detected (Figure 2A and B).
Immunohistochemical analysis of two gastric carcinoma samples
without overexpression of TKTL1 transcript did not reveal TKTL1
protein expression. These results demonstrate a strong correlation
of TKTL1 mRNA and protein expression.
In some cases of undifferentiated gastric carcinoma, strong
nuclear expression was observed (Figure 2H and I). Analysis of
bladder carcinomas showed absence of TKTL1 reactivity in
superficial, nonmuscle-invading tumours (Figure 2J), whereas
invasive tumours showed immunoreactivity (Figure 2K and L).
Non-small-cell lung carcinomas (NSCLC) (Figure 2M), breast
carcinomas (Figure 2N), follicular thyroid carcinomas (FTC)
(Figure 2O), papillary thyroid carcinomas (PTC) (Figure 2P),
prostate carcinomas (Figure 2Q), pancreas carcinomas (Figure 2R;
and undifferentiated thyroid (UTC), ovarian, cervix, rectal, and
kidney carcinomas (not shown) also showed strong upregulation
of TKTL1. Similar to bladder carcinomas, no or weak reactivity for
TKTL1 was observed in noninvasive colon carcinomas (Figure 2S),
whereas in invasive tumours, strong TKTL1 staining was detected
(Figure 2T). All histological variants of thyroid cancer (FTC,
Figure 2O; PTC, Figure 2P; UTC, not shown) revealed abundant
TKTL1 expression within the cytoplasm. Interestingly, the majority
of nuclei were stained in FTC (Figure 2O), whereas in PTC
(Figure 2P), and UTC, (not shown) only few nuclei were TKTL1-
positive. Non-small-cell lung cancer cells were strongly positive for
TKTL1 within the cytoplasm, whereas nuclear staining was absent
(Figure 2M).
Immunohistochemical localisation of TKTL1
protein and activated Akt
Recent studies have demonstrated that activated Akt exerts a direct
influence on glucose metabolism leading to a dose-dependent
stimulation of aerobic glycolysis (Elstrom et al, 2004), and to an
inhibition of b-oxidation of fatty acids (Buzzai et al, 2005).
Therefore, we investigated whether tumours that overexpress the
Table 1 Fold overexpression of transketolase transcripts in colon
carcinomas (T1–5) in comparison to their corresponding normal tissues
T1 T2 T3 T4 T5
TKT 1 1 1 1 1
TKTL1 1 1 1 1 79
TKTL2 1  9500  3  12  375
Negative numbers indicate fold downregulation. Results are mean values of three
independent experiments.
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Figure 1 (A) Quantification of TKTL1 transcripts in gastric carcinoma and lung adenocarcinoma samples, and their corresponding normal tissues. In total,
15ml of the real-time PCR reaction was loaded onto a 3%-agarose gel to visualise the 150bp TKTL1 amplification product. Expression differences between
tumour and corresponding normal tissue were calculated, and are shown as fold induction in tumour sample relative to the corresponding normal sample.
(B) TKTL1 protein expression in tumour and corresponding normal sample of a gastric carcinoma patient with a tumour-specific overexpression of TKTL1
on the transcript level was evaluated by Western blot with antibody JFC12T10. An overexpression of TKTL1 protein was observed in the tumour sample
(T) compared to its corresponding normal tissue (N). Sizes of the protein marker are indicated in kDa.
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indicative of an activated glucose metabolism and an inhibited
b-oxidation of fatty acids. We performed IHC to detect p-Akt in
thyroid, lung, colon, bladder, and prostate cancer specimens
(Figure 3). All the different types of cancer examined showed
strong staining for p-Akt in the cytoplasm, nucleus, and both the
cytoplasm and nucleus, whereas normal tissues showed no or very
weak staining (Figure 3A). In lung, colon, and prostate carcino-
mas, mainly nuclear localisation of p-Akt was seen (Figure 3B,
F and H; yellow arrowheads), whereas in all the histological
variants of thyroid cancer, and bladder cancer, strong cytoplasmic
staining was seen (Figure 3C–E and G). Only few nuclei in PTC
and FTC samples were positive for p-Akt (Figure 3C and D, yellow
arrowheads). Activated Akt was detected in 69% of carcinomas
examined, whereas 83% of tested carcinoma specimens showed
overexpression of TKTL1.
TKTL1 protein is overexpressed in invasive colon
carcinomas and is associated with poor patient survival
In order to study the correlation of TKTL1 expression on clinical–
pathological parameters, a retrospective survey of surgical samples
from 70 patients (55 men and 15 women, median age of 60715
years) with colon adenocarcinoma was performed. Non-neoplastic
colon tissues examined did not reveal TKTL1 expression, and
noninvasive colon cancer specimens were negative or barely
positive for TKTL1 staining (Figure 2S). In contrast, all invasive
colon carcinomas showed TKTL1 expression (Figure 2T), in
particular, 20% were classified as weakly positive for TKTL1 (score
1þ), 25% as positive (score 2þ), and 55% as strongly positive
(score 3þ). A significant correlation between TKTL1 expression
and survival was found (Figure 4A).
TKTL1 protein is overexpressed in invasive urothelial
carcinomas and predicts poor patient survival
To see if the above results could be extended to other tumour
types, we performed a retrospective survey of urothelial carcino-
mas for expression of TKTL1. Of 64 surgical cases, 59 had
malignancies of the urothelial tract. The correlation between
tumour stage and TKTL1 protein staining intensity was 100%
score 0 in pTa superficial carcinomas, 76% score 0 or 1 and 24%
score 2 or 3 in pT1 tumours. Of the muscle-invasive tumours
(XpT2) 3% had score 0, 3% had score 1, 13% had score 2, and 81%
had score 3 TKTL1 staining. There was statistically significant
correlation between staging and staining intensity (Spearman
correlation coefficient 0.836, confidence interval 0.76–0.92).
The overall disease-specific 5-year survival rate was 47% (6 pTa,
14 pT1, 1 cis, 7 pT2). Patients dying because of tumour progression
showed in 83% most intensive staining pattern of the tumours.
Figure 2 Expression of TKTL1 in normal and carcinoma tissues. Specimens of a gastric carcinoma (C–G) and corresponding normal tissue (A, B); (A, B)
no expression of TKTL1 in normal tissue. (C–G) Strong cytoplasmic expression in tumour tissue, but no expression in the surrounding stroma cells. Note
the elevated expression within the inner region of the tumour (F). (H, I) Nuclear TKTL1 expression in a poorly differentiated gastric carcinoma. (J)N o
expression of TKTL1 in a superficial, Ta bladder carcinoma. (K, L) Strong TKTL1 cytoplasmic expression in an invasive, poorly differentiated bladder
carcinoma. Strong TKTL1 upregulation in carcinomas of the lung (non-small-cell lung carcinomas; M), breast (N), thyroid (follicular thyroid carcinoma (O),
papillary thyroid carcinoma (P)), prostate (Q), and pancreas (R). No expression of TKTL1 in a noninvasive colon carcinoma (S), and strong expression in an
invasive colon carcinoma (T). Anti-TKTL1 was revealed by diaminobenzidine tetrahydrochloride (DAB; brown staining) (A–L) and 3-amino-
9-ethylcarbazole (AEC; red staining) (M–T).
TKTL1 in urothelial and colon cancer
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because of other reasons. Of 10 tumours initially found to be
metastatic, nine showed strong overexpression of TKTL1 (grade 3).
The correlation between staining intensity and patient survival was
significant (P¼0.001), and is shown in the Kaplan–Meier plot
(Figure 4B).
DISCUSSION
In 16 epithelial tumour entities we tested, a subgroup of tumours
was found to have upregulated TKTL1 protein. This demonstrates
that TKTL1 upregulation is a general phenomenon in epithelial
malignancies. To determine whether TKTL1 expression correlates
with clinical outcomes of colon and urothelial cancer patients, we
performed a retrospective survey of surgical samples and
determined the survival of patients with tumours expressing
or lacking TKTL1. We found that in colon carcinomas and
urothelial carcinomas, expression of TKTL1 transketolase corre-
lated with invasiveness of tumours and poor patient survival. As
it is important to have diagnostic tests to distinguish between
clinically aggressive and clinically indolent forms of cancer,
our findings demonstrate that the expression of TKTL1 may
indicate which tumours have invasive behaviour leading to poor
patient survival.
Why does TKTL1 overexpression correlate with tumour
invasion? Transketolase enzyme reactions control the nonoxidative
part of the PPP. Using metabolic control analysis methods and
oxythiamine, Comin-Anduix et al (2001) demonstrated that
transketolase enzyme reactions determine cell proliferation in
the Ehrlich’s ascites tumour model. The transketolase enzyme
reactions and other reactions of the PPP allow glucose conversion
to ribose for nucleic acid synthesis and generate NADPH, a
reducing agent required for synthesis reactions. Both of these
products of the PPP are required for growing tumour cells. In
addition, the nonoxidative part of the PPP allows anaerobic
glucose degradation; anaerobic conditions are often present in
tumours and limit the growth of tumours. Even in premalignant
lesions, which are often characterised as highly vascularised, near-
zero partial pressures of oxygen are observed at distances of only
100mm from blood vessels (Gatenby and Gillies, 2004). Tumour
Figure 3 Upregulation of phosphorylated Akt (p-AKT) in epithelial
tumours. Immunohistochemical analysis of p-AKT on paraffin-embedded
sections from normal colon as negative control (A), colon cancer (B),
papillary (PTC) (C), follicular (FTC) (D), undifferentiated thyroid carcinoma
(UTC) (E), non-small-cell lung cancer (NSCLC) (F), bladder cancer (G),
and prostate cancer (H) (red staining). All the different types of cancer
examined showed strong staining for p-Akt (cytoplasmic, nuclear, or both
cytoplasmic and nuclear) while normal tissues showed no or very weak
staining (A). A mainly nuclear localisation of p-Akt was been detected in
colon, lung, and prostate carcinomas (B, F, H; yellow arrowheads). In all
the histological variants of thyroid and bladder cancers, strong cytoplasmic
staining was detectable (C–E, G) and only few nuclei in PTC and FTC
samples were positive for p-Akt (C, D; yellow arrowheads).
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Figure 4 Kaplan–Meier plots demonstrating the significant correlation
between TKTL1 staining intensity and survival in colon carcinoma (A), and
in urothelial carcinoma (B). Scores indicate the fraction of tumour cells in
each sample that stained for TKTL1 protein, as defined in the ‘Materials and
methods’ section.
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glucose as an energy source through nonoxidative generation
of ATP (Coy et al, 2005).
If the changes on the path toward tumorigenic conversion are
seen as a Darwinian selection process conferring a selective growth
advantage, activation of a nonoxidative glucose degradation
pathway is likely to contribute to the individual fitness of such a
tumour cell if anaerobic conditions are present. Mutations in
anaerobic glucose degrading pathways allowing such a selective
growth advantage would represent additional mutations leading to
a fully transformed tumour phenotype. By determining physio-
logical changes in a cell-line model of tumorigenesis, a fully
transformed cell line was most dependent on aerobic glycolysis
and least dependent on the mitochondrial machinery for ATP
synthesis (Ramanathan et al, 2005). During progression to full
transformation, sensitivity to oligomycin, an inhibitor of mito-
chondrial ATP synthase, declined progressively. No decrease in
ATP levels upon treatment with oligomycin was observed in the
fully transformed cell line, consistent with the predominant
production of ATP by aerobic glycolysis (Ramanathan et al,
2005). The fully transformed cell-line was most sensitive to both
2-deoxyglucose and oxamic acid, an inhibitor of lactate dehydro-
genase. The findings in this cell-line model of tumorigenesis
confirm the Warburg effect and the important role of an anaerobic
glucose degradation pathway for tumorigenesis.
Although the molecular and biochemical basis of this metabolic
pathway has been elusive yet, both glucose usage as well as lactate
production are clinically relevant. The glucose usage in tumours
can be noninvasively visualised using PET with the glucose-
analogue tracer, fluorodeoxyglucose (FdG). Furthermore, it has
been shown that both glucose usage and lactate production
represent markers indicating poor prognosis (Di Chiro et al, 1987;
Haberkorn et al, 1991; Downey et al, 2004; Walenta et al, 2004).
The important role of transketolase enzyme reactions for this
glucose degrading and lactate producing pathway has been shown
(Braun et al, 1997; Lee et al, 1998).
The PPP allows nonoxidative glucose degradation and enables a
lactate-based matrix-degradation of the surrounding tissue (Stern
et al, 2002). A lactate-based acidification of the surrounding tissue
may be supplemented by the production of H2CO3 if CO2 is
produced by the oxidative part of the PPP. Both lactate acid and
H2CO3 production lead to excretion of protons and a decline in
pH of the surrounding matrix. This tissue acidosis triggers a
p53-mediated cell death of neighbouring healthy cells (Williams
et al, 1999; Park et al, 2000). Tumour cells survive due to
mutations in p53 or some other components in the apoptosis
pathways. An acid-mediated tumour invasion model including
promotion of angiogenesis, proteolytic cleavage of matrix proteins,
and inhibition of immune response has been proposed (Gatenby
and Gawlinski, 2003).
Although aerobic glycolysis leads to the above-mentioned
selective growth advantages, the most important question remains
unresolved. What is the energetic basis of anaerobic glucose
degradation? An analysis of the contribution of different fuels and
metabolic pathways in proliferating MCF7 breast cancer cells has
demonstrated that 65% of the total ATP turnover is from
unidentified sources (Guppy et al, 2002). Ramanathan et al
(2005) have shown that the fully transformed tumour cell-line does
not show a decrease in ATP levels, even if mitochondrial ATP
production is inhibited. What is the source of ATP in fully
transformed tumour cells when mitochondrial ATP production is
not important?
While considering the above-listed advantages the nonoxidative
PPP confers upon tumour cells, it is important to stress that the
PPP is energetically as inefficient as the anaerobic glucose
degradation via the Embden-Meyerhof pathway. When oxygen is
absent, glucose degradation via both the Embden-Meyerhof
pathway and the PPP leads to lactate production. Muscles perform
the final mitochondrial oxidative steps of oxidative phosphoryla-
tion only if oxygen is present (Pasteur effect; Warburg et al, 1924).
Whereas tumour tissues do not (Warburg et al, 1924). An
unappreciated finding Warburg made was that aerobic glycolysis
occurs in healthy tissues like retina and testis (Warburg et al,
1924). Strikingly, those healthy tissues in which Warburg detected
a high aerobic glycolysis were precisely the same tissues in which a
high level of TKTL1 expression has been observed (Coy et al,
2005). Why do tumour cells still continue to degrade glucose to
lactate even in the presence of oxygen if this anaerobic pathway is
energetically inefficient?
The energetic output of anaerobic glucose degradation, either
based on the Embden-Meyerhof pathway or the PPP reactions as
presented in text books, is worse than the energetic output of
oxidative glucose degradation. Interestingly, the proposed reac-
tions of the nonoxidative PPP are not firmly established;
experimentally measured degree of
14C isotope labelling and its
distribution in carbon atoms of fructose-6-phosphate differs from
that predicted by reaction sequences (Horecker et al, 1954;
Williams et al, 1987; Schenk et al, 1998). This discrepancy
demonstrates the presence of other types of nonoxidative PPP
reactions, although the molecular and biochemical basis of these
reactions remain elusive.
During the evolution of higher vertebrates, mutations in the
TKTL1 gene have led to an altered substrate specificity and altered
enzymatic reaction kinetics. An enhanced, one-substrate reaction
allowing the use of xylulose-5-phosphate as sole substrate has been
detected (Coy et al, 2005). A TKTL1-based lactobacillae-like
glucose degradation pathway has been postulated to explain the
observed glucose metabolism in tumours (Coy et al, 2005), and
such a pathway would result in enhanced glucose usage, enhanced
carbonic anhydrase enzyme activity, enhanced de novo fatty acid
synthesis, inhibition of Embden-Meyerhof glycolysis, enhanced
lactate production, and mitochondria-independent ATP genera-
tion. Such postulated metabolic changes indeed have been
observed in tumours. Enhanced glucose usage (Warburg et al,
1924; Di Chiro et al, 1987; Haberkorn et al, 1991; Downey
et al, 2004), upregulation of carbonic anhydrase IX (Robertson
et al, 2004), fatty acid synthase and de novo fatty acid synthesis
upregulation (Menendez and Lupu, 2004), pyruvate kinase activity
downregulation (Hardt et al, 2004), enhanced lactate production
(Warburg et al, 1924; Walenta et al, 2004), and mitochondria-
independent ATP generation (Warburg et al, 1924; Ramanathan
et al, 2005; Xu et al, 2005) have been detected in tumours, and
most of these metabolic changes are prognostic markers indicating
poor patient survival.
As lactate and pyruvate regulate hypoxia-inducible gene
expression independently of hypoxia by stimulating the accumula-
tion of hypoxia-inducible Factor 1 alpha (Lu et al, 2002), activation
of the TKTL1 pathway leading to lactate and pyruvate may also
contribute to angiogenesis under normoxic conditions.
The presence of the TKTL1 pathway in tumor cells would also
explain why tumor cells with an inhibited mitochondrial respira-
tion and a concomitant enhanced aerobic glycolysis are less
sensitive to induction of apoptosis by common anticancer agents,
but highly sensitive to an inhibition of aerobic glycolysis (Xu et al,
2005). Furthermore, TKTL1-expressing tumours may derive an
additional selective growth advantage if the synthesis of fatty acids
is not reversed by b-oxidation of fatty acids. Recent studies have
shown that this metabolic adaptation for an efficient growth is
present in tumours. In tumours, activated Akt inhibits b-oxidation
of fatty acids (Buzzai et al, 2005). If glucose is available, such a
tumour cell has a selective growth advantage because produced
fatty acids are not degraded; however, this metabolic change leads
to absolute glucose dependence and death, in response to glucose
withdrawal (Elstrom et al, 2004; Buzzai et al, 2005). The
immunohistochemical analysis of expression of TKTL1 and
activated Akt presented here demonstrate that the majority of
TKTL1 in urothelial and colon cancer
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therefore not able to perform b-oxidation of fatty acids.
All the observed metabolic changes in tumours are consistent
with a TKTL1-based, lactobacillae-like glucose metabolism in
tumours. Which of the altered enzymatic activities leading to these
metabolic changes can be exploited for future cancer therapies?
The most effective way to inhibit tumour proliferation should be to
block the generation of energy for tumour growth. Metabolic
control analysis and inhibition of transketolase enzyme reactions
have already shown that tumour proliferation can be inhibited by
anti-transketolase approaches (Rais et al, 1999; Boros et al,
2001a,b; Comin-Anduix et al, 2001, 2002; Du et al, 2004). These
successful results have been attributed to TKT transketolase. The
enzymatic properties of TKTL1 (Coy et al, 2005), its upregulation
in tumours, and the absence of upregulation of TKT and TKTL2
indicate that TKTL1 is the transketolase targeted by anti-
transketolase drugs. The determination of TKTL1 expression in
human malignancies may help to identify cancer patients that
would benefit from an anti-transketolase cancer therapy. As a
proportion of TKTL1 overexpressing tumours does not express
activated Akt, cancer patients with such tumours may benefit from
a concomitant inhibition of fatty acid b-oxidation by activation of
Akt or inhibition of AMPK. Future TKTL1-based anticancer
therapy may also be improved by substrate limitation through
application of a ketogenic diet (Nebeling et al, 1995).
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